Letters to the Editor
Vol. 2 No. 2 (2010): New Drugs and Hemopoietic Stem Cell Transplantation in Oncohematological Diseases of the Elderly
Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: May 31, 2010
1357
Views
677
Downloads
334
HTML
Hematology
Authors
No Abstract Available
Downloads
Download data is not yet available.
Citations
Ethics Approval
Case reportsHow to Cite
“Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia” (2010) Mediterranean Journal of Hematology and Infectious Diseases, 2(2), p. e2010012. doi:10.4084/mjhid.2010.012.
